A recent study from the Department of Genetics, Paul F. Glenn Laboratories for the Biological Mechanisms of Aging Harvard Medical School, Boston,USA; and Department of Pharmacology, School of Medicine, The University of New South Wales, Australia shows that Sirtuin-2 induces the checkpoint kinase BubR1 to increase lifespan. This study was published in the 1 July 2014 issue of the journal “EMBO” by Prof Sinclair, North BJ, and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Small molecule–based Lifespan extension therapy: 17β-E2(An estrogen derivative) increases life span via up regulation of its target gene BubR1. Thus, pharmacological formulations encompassing “17β-E2 or its analogues” may be used to extend the lifespan of an individual.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Undisclosed information: How 17β-E2 increases the expression of BubR1
To cite: Boominathan, Small molecule-based Lifespan extension therapy: 17β-E2(An estrogen derivative) increases life span via up regulation of its target gene BubR1, 11/April/2015, 22.04, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at firstname.lastname@example.org
* Research cooperation